repro

header

repro


Home

Our Aim

Our Services

Contact Us

Repromed International of Pakistan

Store

Home Insemination

Intra-Uterine Insemination

Ovulation Prediction

Pregnancy Tests

Semen Collection

Semen Evaluation

Semen Shipping

Gender Selection

Ultrasound Supplies

Education

PGD Gender Selection

Products

Agents

Cyprus

Disclaimer

FAQ's

Become A Distributor

Distributor Links

Testimonials

Andrology Istitute of Pakistan

 

IVF-M

Repromed is currently not selling any infertility medications due to unavailablility of those medications.

We will notify our clients when those medications will be available in the future.

LG IVF-M™ 75 & 150 IU (Menotropins)
HIGHLY Purified HMG (FSH + LH)

IVF-M
The cost effective solution.
Dose 1 Vial 5 Vials 10 Vials
75 UI $22.50 $100.00 $190.00
150 UI $32.50 $149.50 $290.50

Description:

  • Equivalent brand names: Menopur, Repronex, Merional
  • LG IVF-M™ (Menotropins *) is a highly purified preparation of Human Menopausal Gonatotrophin .
  • Each vial contains 75 IU or 150 IU of FSH + LH.
  • In order to obtain an equivalent of FSH and LG IVF-M™ (Menotropins) is standarised by the addition of hCG (human chorionic gonadotropin)
  • Is indicated for ovulation induction in patients who have previously received pituitary suppression.

Therapeutic Indications for LG IVF-M™ (Menotropins) 75 and 150 IU

  • Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.
  • Stimulation of multifollicular development in patients undergoing assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intrafallopian transfer (GIFT) and zygote intrafallopian transfer (ZIFT).
  • Indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy.

Composition:

  • 1 vial of active ingredient contains: Human Follicle stimulating hormone (FSH) 75 or 150 and Human Luteinizing (LH) 75 or 150

Dosage and Method of administration:

  • Treatment with LG IVF-M™ (Menotropins) should be initiated under the supervision of a physician experienced in the treatment of fertility problems.
  • LG IVF-M™ (Menotropins) is intended for intramuscular and subcutaneous administration. The powder should be reconstituted immediately prior to use with the solvent provided. In order to avoid injection of large volumes up to 5 vials of LG IVF-M™ (Menotropins) 75IU may be dissolved in one ml of solvent.

Male infertility:
Spermatogenesis is stimulated with hCG (1,000 to 2,000 IU hCG 2-3 times per week) then LG IVF-M™ (Menotropins) (75 IU or 150 IU) is administered 2-3 times per week. This treatment should be continued for at least 3 months before any improvement in spermatogenesis can be expected. Current clinical experience indicates that treatment for at least 18 months may be necessary to achieve spermatogenesis.

Females with anovulation (including PCOD):
The objective of treatment with LG IVF-M™ (Menotropins) is to develop a single mature Graafian follicle from which the ovum will be released after the administration of hCG. LG IVF-M™ (Menotropins) may be given as a course of daily injections. In menstruating patients treatment should be started within the first seven days of the menstrual cycle.

The treatment should be adjusted to the individual patient's response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion. A commonly used regimen commences at 75-150IU of LG IVF-M™ (Menotropins) and is increased according to the patient's response. The maximum daily dose is usually not higher than 225IU. If a patient fails to adequately respond after 4 weeks of treatment, the cycle should be abandoned and the patient should recommence at a higher initial dose than in the previous cycle.

When an ideal response is obtained a single injection of 5,000IU-10,000IU of hCG should be administered 24-48hrs after the last LG IVF-M™ (Menotropins) injection. The patient should be recommended to have coitus on the hCG injection day and the following day. Alternatively intrauterine insemination (IUI) may be performed.

In the event of an excessive response treatment should be suspended and hCG withheld (see warnings). Treatment should recommence in the next cycle at a lower dose than in the previous cycle.

Females undergoing controlled ovarian stimulation for multiple follicular development prior to invitro fertilisation or other assisted reproductive technologies.
A commonly used protocol for superovulation involves the administration of 150-225IU of LG IVF-M™ (Menotropins) daily commencing on days 2 or 3 of the cycle and continued until sufficient follicular development has been achieved as assessed by monitoring of serum oestrogen concentrations and/or ultrasound examination with the dose adjusted according to the patient's response but usually not higher than 450IU daily. Adequate follicular development is usually achieved by the tenth day of treatment (range 5-20 days).

A single injection of 5,000IU-10,000IU of hCG should be administered 24-48 hours after the last LG IVF-M™ (Menotropins) injection to induce follicular maturation.

Pituitary down-regulation in order to supress the endogenous LH surge and to control tonic levels of LH is now commonly achieved by administration of a gonadotrophin releasing hormone (GnRH) agonist. In a commonly used protocol the administration of LG IVF-M™ (Menotropins) is started approximately two weeks after the start of agonist treatment, both being continued until adequate follicular development has been achieved. For example, following two weeks of pituitary down-regulation with an agonist, 150-225IU of LG IVF-M™ (Menotropins) are administered for seven days; the dose is then adjusted according to the patient's ovarian response.

Experience with ART indicates that in general the treatment success rate remains stable during the first four attempts and gradually declines thereafter.

Females with anovulation resulting from severe LH and FSH deficiency.
In these women (hypogonadotrophic hypogonadism) the objective of LG IVF-M™ (Menotropins) treatment is to develop a single mature Graafian follicle from which the oocyte will be released following the administration of hCG. As these women are amenorrhoeic and have low endogenous oestrogen secretion treatment may commence at any time.

The treatment should be adjusted to the individual patient's response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion. A commonly used regimen commences at 75-150IU of LG IVF-M™ (Menotropins) and is increased according to the patient's response. Should an increased dose of LG IVF-M™ (Menotropins) be deemed appropriate, dose adaptation should preferably be made after 7-14 day intervals and preferably by 75IU increments. It may be acceptable to extend the duration of stimulation in any one cycle up to 5 weeks.

When an ideal response is obtained a single injection of 5,000IU-10,000IU of hCG should be administered 24-48hrs after the last LG IVF-M™ (Menotropins) injection. The patient should be recommended to have coitus on the hCG injection day and the following day. Alternatively intrauterine insemination (IUI) may be performed.

Luteal phase support may be considered since lack of substances with luteotrphic activity (LH/hCG) after ovulation may lead to a premature loss of the corpus luteum.

In the event of an excessive response treatment should be suspended and hCG withheld (see warnings). Treatment should recommence in the next cycle at a lower dose than in the previous cycle.

Treatment in Women

Before starting treatment, the couple's infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated. In particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency hyperprolactinemia and pituitary or hypothalamic tumours, and appropriate specific treatment given.

Patients undergoing stimulation of follicular growth whether in the frame of a treatment for anovulatory infertility or ART procedures, may experience ovarian enlargement or develop hyperstimulation. Adherence to recommended LG IVF-M™ (Menotropins) dosage and regimen of administration, and careful monitoring of therapy will minimize the incidence of such events.

Accurate interpretation of the indices of follicular development and maturation require a physician who is experienced in the interpretation of such data

Treatment in Males

Elevated endogenous FSH levels are indicative of primary testicular failure. Such patients are unresponsive to LG IVF-M™ (Menotropins)/hCG therapy Semen analysis is recommended 4-6 months after the beginning of treatment in assessing the response.

 

 

Home Semen Analysis

conceive

 

Repromed International

Request interview with Dr Zavos

   


Affiliates

The following websites are affiliated with Repromed International.


images/affiliates.gif

ZDLinc.biz

Dr Zavos in the news

Andrology Institute of America

Fertility Zone

Fert Mart

Ebay

Home Gender Selection

 

 Copyright © 2010 Repromed International

Totalserve HouseA
17, Gr. Xenopoulou Street
3106 Limassol, Cyprus
P.O Box 54425
3724 Limassol, Cyprus
dvs

SSL